Mammary fat necrosis following radiotherapy in the conservative management of localized breast cancer: does it matter?

Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
Radiotherapy and Oncology (Impact Factor: 4.86). 03/2010; 97(1):92-4. DOI: 10.1016/j.radonc.2010.02.021
Source: PubMed

ABSTRACT Fat necrosis is a well-described and relatively common complication arising from post-lumpectomy irradiation of the breast, most commonly breast brachytherapy. We wish to assess the clinical significance of fat necrosis resulting from post-lumpectomy breast irradiation.
We reviewed the literature to determine the overall incidence and significance of fat necrosis to determine whether or not fat necrosis poses a significant clinical problem.
Fat necrosis occurs in up to one-quarter of patients following post-lumpectomy breast irradiation. Only rarely is invasive intervention required however, it does significantly degrade the quality of all modalities of breast imaging.
Fat necrosis is a common complication of radiotherapy which rarely requires therapeutic intervention. However, post-therapeutic clinical imaging such as mammography, ultrasound and magnetic resonance imaging are affected which may result in additional diagnostic procedures up to and including biopsy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Connective vascular diseases (CVD), including scleroderma, are reported to represent for some researchers a relative contraindication and for others absolute contraindication for radiotherapy. The purpose of our study is to add four new cases to the existing body of international literature and to determine whether women with pre-existing scleroderma who have been surgically treated for early breast cancer could undergo postsurgical radiotherapy without serious early and late complications. From May 1998 to November 2010, we irradiated for early breast cancer four patients suffering from pre-existing scleroderma; after conservative surgery, we performed whole breast postoperative radiotherapy of 50.4 Gy total dose to the whole breast plus a 9 Gy boost to the tumor bed. We reviewed the records of all four patients and evaluated the early and late reactions using acute radiation morbidity scoring criteria (Radiation Therapy Oncology Group [RTOG], American College of Radiology, Philadelphia, PA) and late radiation morbidity scoring scheme (European Organisation for Research and Treatment of Cancer [EORTC], Brussels, Belgium and RTOG). After a median follow-up of 105 months (range 12-155 months) the early and late toxicity concerning the skin, the subcutaneous tissues, the lungs, and the heart have been acceptable and are in full accordance with what have been reported in international literature. This study matches global experience, which shows that patients with scleroderma and breast cancer must be discussed by the multidisciplinary tumor board in order for a personalized treatment strategy to be formulated. Radiation therapy can be proposed as a postsurgical therapeutic option in selected cases.
    Breast Cancer: Targets and Therapy 01/2012; 4:3-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The aim of this retrospective analysis was to evaluate mammographic changes such as fat necroses and parenchymal scarring in the breast tissue within the first 3 years after breast-conserving surgery (BCS) and whole-breast irradiation with an additional intraoperative electron boost (IO-B) versus fractionated percutaneous boost (FP-B). METHODS: A total of 53 breast cancer patients (stage I/II) treated between 2006 and 2008 were included. All patients underwent BCS followed by fractionated whole-breast radiotherapy with a total dose and single dose of 50.4 and 1.8 Gy. Twenty patients had 10 Gy IO-B using electrons, and 33 patients were treated with a FP-B with 10.8 Gy. The IO-B was performed using the mobile linear accelerator NOVAC 7. The follow-up mammograms were focused on fat necroses, parenchymal scarring and skin thickening. RESULTS: Fat necroses occurred significantly more frequently in IO-B patients compared to FP-B patients (50.0 vs. 18.2 %). The fat necroses were mammographically detected a median of 17 versus 23 months post-surgery for the IO-B versus FP-B patients. The median size of fat necroses was 24 (14-30) mm for the IO-B group and 14 (4-53) mm for the FP-B group. Parenchymal scarring in the grade 3-4 tumor bed area was seen significantly more frequently in the IO-B patients (55.0 vs. 21.2 %). Skin thickening did not differ significantly. CONCLUSION: The IO-B led to significantly more fat necroses and local restricted parenchymal scarring in our analysis.
    Breast Cancer 10/2012; 21(4). · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Excision of breast cancer followed by radiofrequency ablation (eRFA) is a technique designed to increase negative margins in breast conservative surgery. The objective of this study is to analyze the impact of the eRFA in avoiding a second surgery for close or positive margins after BCS. Material and Methods From February 2008 to May 2010, 20 patients were included. After lumpectomy, the eRFA was performed in the lumpectomy cavity and biopsies from each margin from the radial ablated cavity walls were obtained. Biopsies were assessed for tumor viability. Results eRFA was successful in 19 patients. In all patients the devitalized tissue extended beyond the 5-10 mm radial depth of the biopsy sample. Six patients (31%) had margins < 2 mm in the final pathology, 4 of them with < 1 mm margin. All the 6 patients had no tumor viability after stained by Triphenyltetrazolium chloride in the biopsies from the cavity wall. At a median follow-up of 46 months, no local recurrences have occurred. Conclusions This study supports the feasibility of eRFA cavity treatment. The e-RFA has spared 31% of patients to undergo a re-excision surgery and it may, in the long term, reduce local recurrences.
    Clinical Breast Cancer 10/2014; · 2.63 Impact Factor